TY - CHAP M1 - Book, Section TI - CARDIOVASCULAR DISEASE IN THE ELDERLY: PATHOPHYSIOLOGY AND CLINICAL IMPLICATIONS A1 - Stolker, Joshua M. A1 - Kim, Dae H. A1 - Rich, Michael W. A2 - Fuster, Valentin A2 - Harrington, Robert A. A2 - Narula, Jagat A2 - Eapen, Zubin J. Y1 - 2017 N1 - T2 - Hurst's The Heart, 14e AB - Most cardiovascular diseases (CVDs) increase in prevalence and severity with age, and most clinicians provide care for a substantial number of elderly patients with disorders of the heart and vascular system. According to the American Heart Association, nearly 70% of all US adults ≥ 60 years old and more than 85% of those ≥ 80 years old have known CVD (Fig. 65–1).1 Despite earlier treatment of risk factors and progressive improvements in therapies over the past several decades, heart disease remains the leading cause of death in the Medicare population. Furthermore, more than half of all cardiovascular procedures in the United States are performed in patients aged 65 years and older, and the total cost for CVD in this population exceeded $115 billion in 2011.1 With the progressive aging of our population,2,3 these figures will continue to rise. For these reasons, an understanding of the effects of aging on the development of CVD and the utility of cardiovascular therapies in the context of other age-related medical concerns (eg, multimorbidity, polypharmacy, frailty) is critical for reducing risk and improving outcomes in older patients. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1161715781 ER -